Cargando…

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer

As an aggressive subtype of breast cancer, triple-negative breast cancer (TNBC) is associated with poor prognosis and lack of effective therapy, except chemotherapy. In recent years, immunotherapy based on immune checkpoint (IC) inhibition has emerged as a promising therapeutic strategy in TNBC. TNB...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Qiaorui, Yin, Sha, Zhou, Dongdong, Chi, Yajing, Man, Xiaochu, Li, Huihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134495/ https://www.ncbi.nlm.nih.gov/pubmed/35646659 http://dx.doi.org/10.3389/fonc.2022.779786

Ejemplares similares

Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer
por: Tan, Qiaorui, et al.
Publicado: (2023)

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression
por: Shang, Mao, et al.
Publicado: (2022)

Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study
por: Yin, Sha, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
por: Huertas-Caro, Carlos Alexander, et al.
Publicado: (2022)

The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages
por: Sun, Shujuan, et al.
Publicado: (2023)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer
por: Zhou, Jialin, et al.
Publicado: (2022)

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
por: Scarpa, Joseph R., et al.
Publicado: (2023)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer
por: Zhou, Yueyuan, et al.
Publicado: (2022)

Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer
por: Zhang, Hao, et al.
Publicado: (2023)

Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis
por: Wu, Qiang, et al.
Publicado: (2019)

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Li, Yunhai, et al.
Publicado: (2021)

SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
por: Zhu, Youzhi, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Ji, Qiao, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
por: Qureshi, Sadaf, et al.
Publicado: (2022)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study
por: Jiang, Weihua, et al.
Publicado: (2021)

Prognostic Biomarkers on a Competitive Endogenous RNA Network Reveals Overall Survival in Triple-Negative Breast Cancer
por: Qin, Wenxing, et al.
Publicado: (2021)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021)

Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer
por: Hu, Zhe-Yu, et al.
Publicado: (2022)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
por: Zhang, Siheng, et al.
Publicado: (2023)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Comprehensive Analysis of TRP Channel–Related Genes in Patients With Triple-Negative Breast Cancer for Guiding Prognostic Prediction
por: Zhang, Haojie, et al.
Publicado: (2022)

Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer
por: Li, Meng, et al.
Publicado: (2022)

Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer
por: Ding, Ran, et al.
Publicado: (2023)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Transcriptome Analysis Reveals MFGE8-HAPLN3 Fusion as a Novel Biomarker in Triple-Negative Breast Cancer
por: Wang, Meng-Yuan, et al.
Publicado: (2021)

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
por: Jessurun, Charissa A. C., et al.
Publicado: (2017)

Survival analysis and nomogram for early-stage occult breast cancer with positive lymph nodes based on the SEER database
por: Man, Xiaochu, et al.
Publicado: (2022)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
por: Di Spazio, Lorenzo, et al.
Publicado: (2022)

Targeted Therapeutic Strategies for Triple-Negative Breast Cancer
por: Li, Ying, et al.
Publicado: (2021)

Novel Prognostic Markers in Triple-Negative Breast Cancer Discovered by MALDI-Mass Spectrometry Imaging
por: Phillips, Leo, et al.
Publicado: (2019)

Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer
por: Wu, Song, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9ftl4da7htq1o9vl98atl6fhjj